# Abingworth LLP

> Institutional holdings reported to the SEC as of Q4 2022 on Form 13F. CIK 1397144. Source: https://holderbook.com/funds/1397144-abingworth-llp/

- Reported value: $306.9M
- Positions: 19
- Weight of the ten largest: 96.9%
- Filed: 2023-02-10

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| VAXCYTE INC | [PCVX](https://holderbook.com/stocks/PCVX/) | $96.8M | 2,019,057 | 31.5% | 11 |
| VERONA PHARMA PLC | [VRNA](https://holderbook.com/stocks/VRNA/) | $64.2M | 2,457,500 | 20.9% | 17 |
| VERA THERAPEUTICS INC | [VERA](https://holderbook.com/stocks/VERA/) | $57.3M | 2,960,231 | 18.7% | 7 |
| HILLEVAX INC | [HLVX](https://holderbook.com/stocks/HLVX/) | $30.8M | 1,838,486 | 10.0% | 3 |
| ADICET BIO INC | [ACET](https://holderbook.com/stocks/ACET/) | $18.9M | 2,115,385 | 6.2% | 8 |
| PHATHOM PHARMACEUTICALS INC | [PHAT](https://holderbook.com/stocks/PHAT/) | $16.1M | 1,435,106 | 5.2% | 13 |
| RENEO PHARMACEUTICALS INC | [RPHM](https://holderbook.com/stocks/RPHM/) | $4.8M | 2,073,957 | 1.6% | 7 |
| SIENTRA INC | [SIENXXXX](https://holderbook.com/stocks/SIENXXXX/) | $3.4M | 1,673,589 | 1.1% | 17 |
| JASPER THERAPEUTICS INC | [JSPRXXXX](https://holderbook.com/stocks/JSPRXXXX/) | $2.7M | 5,628,558 | 0.9% | 6 |
| SOLENO THERAPEUTICS INC | [SLNO](https://holderbook.com/stocks/SLNO/) | $2.4M | 1,201,506 | 0.8% | 2 |
| NUCANA PLC | [NCNA](https://holderbook.com/stocks/NCNA/) | $2.2M | 3,333,333 | 0.7% | 10 |
| EFFECTOR THERAPEUTICS INC | [EFTR](https://holderbook.com/stocks/EFTR/) | $2.1M | 4,822,114 | 0.7% | 6 |
| SPRUCE BIOSCIENCES INC | [SPRB](https://holderbook.com/stocks/SPRB/) | $2.0M | 1,792,518 | 0.6% | 2 |
| PARATEK PHARMACEUTICALS INC | [PRTK](https://holderbook.com/stocks/PRTK/) | $1.9M | 1,041,131 | 0.6% | 17 |
| CYMABAY THERAPEUTICS INC | [CBAY](https://holderbook.com/stocks/CBAY/) | $821.6K | 131,036 | 0.3% | 17 |
| EXICURE INC | [XCUR](https://holderbook.com/stocks/XCUR/) | $323.9K | 281,636 | 0.1% | 2 |
| AEGLEA BIOTHERAPEUTICS INC | [AGLE](https://holderbook.com/stocks/AGLE/) | $108.2K | 240,500 | 0.0% | 16 |
| MOLECULAR TEMPLATES INC | [MTEM](https://holderbook.com/stocks/MTEM/) | $66.0K | 200,000 | 0.0% | 13 |
| OBSEVA SA | [OBSVF](https://holderbook.com/stocks/OBSVF/) | $12.8K | 87,999 | 0.0% | 17 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q4 2022 | +39.0% | +7.1% | +32.0% | 100% |
| Q3 2022 | +22.8% | -5.3% | +28.2% | 75% |
| Q2 2022 | -29.0% | -16.5% | -12.5% | 87% |
| Q1 2022 | -21.5% | -4.9% | -16.6% | 94% |
| Q4 2021 | -8.2% | +10.7% | -18.9% | 93% |
| Q3 2021 | -0.3% | +0.3% | -0.6% | 89% |
| Q2 2021 | -6.4% | +8.0% | -14.4% | 85% |
| Q1 2021 | -5.4% | +6.0% | -11.4% | 81% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q4 2022 | $306.9M | 19 |
| Q3 2022 | $292.5M | 19 |
| Q2 2022 | $312.4M | 21 |
| Q1 2022 | $352.5M | 20 |
| Q4 2021 | $412.7M | 20 |
| Q3 2021 | $440.7M | 20 |
| Q2 2021 | $323.5M | 19 |
| Q1 2021 | $289.6M | 17 |
| Q4 2020 | $292.3M | 15 |
| Q3 2020 | $467.5M | 17 |
| Q2 2020 | $357.7M | 16 |
| Q1 2020 | $150.6M | 16 |